P300 acetyltransferase regulates androgen receptor degradation and pten-deficient prostate tumorigenesis

Cancer Research

Volumn 74, Issue 6, 2014, Pages 1870-1880

  Zhong, Jian ^a,b,d   Ding, Liya ^a,b,d   Bohrer, Laura R ^e   Pan, Yunqian ^a   Liu, Ping ^e   Zhang, Jun ^c   Sebo, Thomas J ^c   Karnes, R Jeffrey ^b   Tindall, Donald J ^b,d   Van Deursen, Jan ^a,d   Huang, Haojie ^a,b,d  

^a MAYO CLINIC   (United States)

^b Urology and Laboratory Medicine   (United States)

^c Laboratory Medicine and Pathology   (United States)

^d Mayo Clinic Cancer Center Mayo Clinic College of Medicine   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; E1A ASSOCIATED P300 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME BINDING; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; HISTONE ACETYLATION; HISTONE UBIQUITINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; P300 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; PTEN GENE; RNA INTERFERENCE; TRANSCRIPTION INITIATION;

AGED; ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; P300-CBP TRANSCRIPTION FACTORS; PHOSPHORYLATION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEOLYSIS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC; UBIQUITINATION;

EID: 84896518278     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2485     Document Type: Article

References (49)

1. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-90. (Pubitemid 39315314)
2. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984;5:545-57. (Pubitemid 14016047)
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61. (Pubitemid 46211563)
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
6. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
7. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
8. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
9. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4: 209-21. (Pubitemid 37163835)
10. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
11. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005; 65:5730-9. (Pubitemid 40911176)
12. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-77. (Pubitemid 30460905)
13. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638-40. (Pubitemid 37466688)
14. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004;10:1032-40. (Pubitemid 38202234)
15. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, et al. p300 and p300/cAMP-response element-binding protein-Associated factor acetylate the androgen receptor at sites governing hormonedependent transactivation. J Biol Chem 2000;275:20853-60. (Pubitemid 30457679)
16. Fu M, Rao M,WangC, Sakamaki T,WangJ, Di Vizio D, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003;23:8563-75. (Pubitemid 37433362)
17. Gong J, Zhu J, Goodman OB Jr., Pestell RG, Schlegel PN, Nanus DM, et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 2006;25:2011-21.
18. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgenindependent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62:5632-6. (Pubitemid 35204712)
19. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, et al. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 2002;22:3373-88. (Pubitemid 34453978)
20. Popov VM, Wang C, Shirley LA, Rosenberg A, Li S, Nevalainen M, et al. The functional significance of nuclear receptor acetylation. Steroids 2007;72:221-30. (Pubitemid 46273505)
21. Liu P, Kao TP, Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 2008;27:4733-44.
22. Kasper LH, Fukuyama T, Biesen MA, Boussouar F, Tong C, de Pauw A, et al. Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol 2006;26:789-809. (Pubitemid 43146476)
23. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001;101:61-9. (Pubitemid 32186310)
24. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, et al. Cyclindependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 2010;12:1108-14.
25. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Ptendeficient tumorigenesis. Nature 2005;436:725-30. (Pubitemid 41117277)
26. Santer FR, Hoschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 2011;10:1644-55.
27. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011;19:792-804.
28. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007;67:6083-91. (Pubitemid 47037487)
29. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86.
30. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylationdependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002;21:4037-48. (Pubitemid 34857436)
31. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002;277:50607-11. (Pubitemid 36042220)
32. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A 2006;103:15969-74. (Pubitemid 44657576)
33. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-Trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1999;96:6199-204. (Pubitemid 29256643)
34. Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 2001;11:263-7. (Pubitemid 32185329)
35. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000;20: 8969-82. (Pubitemid 32245927)
36. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2002;2:81-91. (Pubitemid 41043990)
37. Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, et al. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005;65:708-12. (Pubitemid 40216426)
38. Debes JD, Comuzzi B, Schmidt LJ,Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostatespecific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 2005;65:5965-73. (Pubitemid 40911204)
39. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-Terminal domain. Cell 1997;90: 595-606. (Pubitemid 27357952)
40. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44:1310-5.
41. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 2010;24:2267-80.
42. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 2012;287:8571-83.
43. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007;67:3422-30. (Pubitemid 46724883)
44. Fu M, Wang C, Zhang X, Pestell RG. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 2004;68: 1199-208. (Pubitemid 39094285)
45. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
46. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-34.
47. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, et al. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 2011;75:2151-9.
48. Choi KC, Park S, Lim BJ, Seong AR, Lee YH, Shiota M, et al. Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor. Biochem J 2011;433:235-44.
49. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009; 125:1-8.